Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), ...
J.P. Morgan analyst Chris Schott maintained a Buy rating on Perrigo Company (PRGO – Research Report) today and set a price target of ...
Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...
AstraZeneca, the UK’s largest drugmaker valued at $140bn, has reportedly contacted Gilead Sciences, an American biopharmaceutical company with a market value of approximately $96bn, regarding a ...
Zacks.com on MSN10h
Gilead, MRK Report Data From Investigational Combination Study for HIVGilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
Here are some regions that are attracting biotech and pharma companies.
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Medpage Today on MSN7d
Novel Drug Effective Against MASH in Phase II TrialAn investigational oral fatty acid synthase (FASN) inhibitor was associated with significant improvements in metabolic ...
“The RFK announcement has kind of scrambled some of the traditional thinking [about] a lot of the people that have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback